

# Agnes Jager

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6086641/publications.pdf>

Version: 2024-02-01

132  
papers

8,168  
citations

76326

40  
h-index

51608

86  
g-index

137  
all docs

137  
docs citations

137  
times ranked

13725  
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer. <i>Clinical Pharmacokinetics</i> , 2022, 61, 527-537.	3.5	17
2	Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. <i>Breast</i> , 2022, 61, 98-107.	2.2	6
3	Rare germline copy number variants (CNVs) and breast cancer risk. <i>Communications Biology</i> , 2022, 5, 65.	4.4	6
4	Pharmacological CDK4/6 inhibition reveals a p53-dependent senescent state with restricted toxicity. <i>EMBO Journal</i> , 2022, 41, e108946.	7.8	35
5	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. <i>Cancer Treatment Reviews</i> , 2022, 104, 102340.	7.7	21
6	Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210810.	3.2	2
7	Abstract P2-01-17: Circulating tumor cell count and levels of circulating tumor DNA are complementary prognostic biomarkers in metastatic breast cancer - A pilot study. <i>Cancer Research</i> , 2022, 82, P2-01-17-P2-01-17.	0.9	1
8	Functional Ex Vivo Tissue-Based Chemotherapy Sensitivity Testing for Breast Cancer. <i>Cancers</i> , 2022, 14, 1252.	3.7	4
9	Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review. <i>Cancer Treatment Reviews</i> , 2022, 106, 102384.	7.7	12
10	The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction. <i>International Journal of Cancer</i> , 2022, , .	5.1	1
11	Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study. <i>Breast Cancer Research and Treatment</i> , 2022, , .	2.5	1
12	Clinical Validity of $^{18}\text{F}$ -Fluoro-17 $\beta$ -Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3642-3652.	1.6	21
13	Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests. <i>Oncogene</i> , 2022, 41, 3498-3506.	5.9	9
14	Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?. <i>BMC Cancer</i> , 2022, 22, .	2.6	0
15	Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 205-214.	2.5	19
16	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021, 124, 842-854.	6.4	5
17	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	12.8	19
18	Abstract GS1-10: Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: Results of the prospective multicenter RISAS trial. <i>Cancer Research</i> , 2021, 81, GS1-10-GS1-10.	0.9	17

#	ARTICLE	IF	CITATIONS
19	Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation. <i>Cancers</i> , 2021, 13, 1004.	3.7	28
20	The added value of H2 antagonists in premedication regimens during paclitaxel treatment. <i>British Journal of Cancer</i> , 2021, 124, 1647-1652.	6.4	14
21	Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?. <i>Cancers</i> , 2021, 13, 2506.	3.7	17
22	Measuring Quality of Life Using Patient-Reported Outcomes in Real-World Metastatic Breast Cancer Patients: The Need for a Standardized Approach. <i>Cancers</i> , 2021, 13, 2308.	3.7	10
23	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021, 108, 1190-1203.	6.2	6
24	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, 86.	5.0	7
25	Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel. <i>Cancers</i> , 2021, 13, 3915.	3.7	2
26	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021, 125, 1135-1145.	6.4	9
27	Ovarian Cancer-Specific <i>BRCA</i> -like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6559-6569.	7.0	9
28	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 623-642.	2.5	19
29	Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 2798-2806.	7.0	14
30	The changing microRNA landscape by color and cloudiness: a cautionary tale for nipple aspirate fluid biomarker analysis. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1339-1349.	4.4	4
31	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.9	39
32	Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1). <i>Investigational New Drugs</i> , 2020, 38, 1117-1128.	2.6	10
33	Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). <i>Investigational New Drugs</i> , 2020, 38, 1096-1107.	2.6	11
34	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
35	Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 83, 101951.	7.7	26
36	High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2 <sup>-</sup> postmenopausal breast cancer patients treated with everolimus and exemestane. <i>Molecular Oncology</i> , 2020, 14, 490-503.	4.6	14

#	ARTICLE	IF	CITATIONS
37	From Multiple Quality Indicators of Breast Cancer Care Toward Hospital Variation of a Summary Measure. <i>Value in Health</i> , 2020, 23, 1200-1209.	0.3	7
38	Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab. <i>Breast</i> , 2020, 52, 71-77.	2.2	11
39	Clinical decision trees support systematic evaluation of multidisciplinary team recommendations. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 355-363.	2.5	5
40	Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 107-113.	2.5	14
41	Prognostic factors in patients with oligometastatic breast cancer – A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 91, 102114.	7.7	24
42	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
43	Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice. <i>Breast</i> , 2020, 52, 33-44.	2.2	26
44	The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer. <i>Breast</i> , 2020, 52, 102-109.	2.2	2
45	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 423-434.	2.5	14
46	Effect of Case-Mix and Random Variation on Breast Cancer Care Quality Indicators and Their Rankability. <i>Value in Health</i> , 2020, 23, 1191-1199.	0.3	9
47	Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 723-733.	2.5	111
48	The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. <i>Nature Genetics</i> , 2019, 51, 1450-1458.	21.4	250
49	Transformation of the National Breast Cancer Guideline Into Data-Driven Clinical Decision Trees. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-14.	2.1	15
50	53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 153, 127-134.	1.4	56
51	Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence. <i>Journal of Clinical Oncology</i> , 2019, 37, 1980-1981.	1.6	18
52	Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 383-393.	2.5	12
53	MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. <i>PLoS ONE</i> , 2019, 14, e0216400.	2.5	54
54	Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. <i>Cancers</i> , 2019, 11, 403.	3.7	31

#	ARTICLE	IF	CITATIONS
55	Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 1083-1089.	5.1	27
56	Direct Ex Vivo Observation of Homologous Recombination Defect Reversal After DNA-Damaging Chemotherapy in Patients With Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	3.0	13
57	Prediction and clinical utility of a contralateral breast cancer risk model. <i>Breast Cancer Research</i> , 2019, 21, 144.	5.0	24
58	Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1355-1360.	3.7	20
59	Novel methods to diagnose leptomeningeal metastases in breast cancer. <i>Neuro-Oncology</i> , 2019, 21, 428-439.	1.2	10
60	An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 123-137.	2.8	15
61	Severe sarcopenia might be associated with a decline of physical independence in older patients undergoing chemotherapeutic treatment. <i>Supportive Care in Cancer</i> , 2018, 26, 1781-1789.	2.2	19
62	A nationwide registry-based cohort study of the MammaPrint genomic risk classifier in invasive breast cancer. <i>Breast</i> , 2018, 38, 125-131.	2.2	9
63	Heat-induced BRCA2 degradation in human tumours provides rationale for hyperthermia-PARP-inhibitor combination therapies. <i>International Journal of Hyperthermia</i> , 2018, 34, 407-414.	2.5	20
64	Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients. <i>Molecular Oncology</i> , 2018, 12, 48-57.	4.6	52
65	Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 95-105.	2.5	37
66	Functional <i>Ex Vivo</i> Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects. <i>Clinical Cancer Research</i> , 2018, 24, 6277-6287.	7.0	53
67	Potential cost savings owing to the route of administration of oncology drugs. <i>Anti-Cancer Drugs</i> , 2018, 29, 791-801.	1.4	23
68	<i>Ex vivo</i> tumor culture systems for functional drug testing and therapy response prediction. <i>Future Science OA</i> , 2017, 3, FSO190.	1.9	117
69	A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study. <i>Clinical Breast Cancer</i> , 2017, 17, 399-402.	2.4	91
70	Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	55
71	First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy. <i>Oncologist</i> , 2017, 22, 901-909.	3.7	18
72	Omitting re-excision for focally positive margins after breast-conserving surgery does not impair disease-free and overall survival. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 157-167.	2.5	37

#	ARTICLE	IF	CITATIONS
73	Clinical auditing as an instrument for quality improvement in breast cancer care in the Netherlands: The national NABON Breast Cancer Audit. <i>Journal of Surgical Oncology</i> , 2017, 115, 243-249.	1.7	62
74	Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. <i>Breast</i> , 2017, 31, 9-15.	2.2	109
75	ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients. <i>Cancer Treatment Reviews</i> , 2017, 52, 33-40.	7.7	75
76	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. <i>Oncotarget</i> , 2017, 8, 18381-18398.	1.8	14
77	A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial. <i>Cancer</i> , 2016, 122, 2961-2970.	4.1	7
78	Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 557-566.	2.5	19
79	The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. <i>Oncologist</i> , 2016, 21, 1396-1409.	3.7	147
80	Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. <i>Neoplasia</i> , 2016, 18, 647-653.	5.3	44
81	Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 179-187.	2.5	42
82	Tumor slice culture system to assess drug response of primary breast cancer. <i>BMC Cancer</i> , 2016, 16, 78.	2.6	114
83	An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 123.	2.6	25
84	Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1251-1258.	2.5	9
85	Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 1611-1620.	7.0	27
86	Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. <i>Clinical Pharmacokinetics</i> , 2016, 55, 249-255.	3.5	21
87	Atypical femur fractures and use of bisphosphonates. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2016, 13, 204-208.	1.0	7
88	Understanding drugs in breast cancer through drug sensitivity screening. <i>SpringerPlus</i> , 2015, 4, 611.	1.2	11
89	A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 978.	2.6	6
90	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	5.0	26

#	ARTICLE	IF	CITATIONS
91	Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature. <i>Cancer Treatment Reviews</i> , 2015, 41, 187-196.	7.7	47
92	Circulating tumor cell enumeration by the CellSearch system: The clinician's guide to breast cancer treatment?. <i>Cancer Treatment Reviews</i> , 2015, 41, 144-150.	7.7	62
93	Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping. <i>Cancer Treatment Reviews</i> , 2015, 41, 289-299.	7.7	95
94	Overall survival in patients with a re-excision following breast conserving surgery compared to those without in a large population-based cohort. <i>European Journal of Cancer</i> , 2015, 51, 282-291.	2.8	31
95	Development and validation of an UPLC-MS/MS method for the quantification of tamoxifen and its main metabolites in human scalp hair. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 114, 416-425.	2.8	16
96	Neutrophil-guided dosing of anthracycline-cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study. <i>Medical Oncology</i> , 2015, 32, 113.	2.5	5
97	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. <i>Breast Cancer Research</i> , 2015, 17, 18.	5.0	20
98	Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. <i>Cancer Letters</i> , 2015, 362, 36-44.	7.2	41
99	The effect of immediate breast reconstruction on the timing of adjuvant chemotherapy: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 241-251.	2.5	59
100	Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 171-180.	2.5	32
101	Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1879-1887.	2.5	10
102	Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 119-128.	2.5	30
103	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 285-298.	2.9	38
104	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. <i>Oncotarget</i> , 2015, 6, 7390-7407.	1.8	15
105	MicroRNA Related Polymorphisms and Breast Cancer Risk. <i>PLoS ONE</i> , 2014, 9, e109973.	2.5	49
106	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. <i>Human Molecular Genetics</i> , 2014, 23, 1934-1946.	2.9	32
107	Functional <i>Ex Vivo</i> Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment. <i>Clinical Cancer Research</i> , 2014, 20, 4816-4826.	7.0	144
108	Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 923-929.	2.5	56

#	ARTICLE	IF	CITATIONS
109	The risk of primary and contralateral breast cancer after ovarian cancer in <i>BRCA1</i> / <i>BRCA2</i> mutation carriers. <i>Cancer</i> , 2013, 119, 955-962.	4.1	31
110	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
111	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013, 45, 353-361.	21.4	960
112	Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. <i>Breast</i> , 2013, 22, 13-18.	2.2	52
113	Breast fine-needle aspiration cytology performance in the high-risk screening population. <i>Cancer Cytopathology</i> , 2013, 121, 561-567.	2.4	9
114	A Nonsynonymous Polymorphism in <i>IRS1</i> Modifies Risk of Developing Breast and Ovarian Cancers in <i>BRCA1</i> and Ovarian Cancer in <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1362-1370.	2.5	23
115	The role of genetic breast cancer susceptibility variants as prognostic factors. <i>Human Molecular Genetics</i> , 2012, 21, 3926-3939.	2.9	80
116	9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1783-1791.	2.5	17
117	Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors. <i>Cancer</i> , 2012, 118, 6005-6011.	4.1	57
118	Efficacy of opioid rotation to continuous parenteral hydromorphone in advanced cancer patients failing on other opioids. <i>Supportive Care in Cancer</i> , 2012, 20, 1639-1647.	2.2	10
119	The efficacy of taxane chemotherapy for metastatic breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Cancer</i> , 2012, 118, 899-907.	4.1	83
120	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. <i>Journal of the National Cancer Institute</i> , 2011, 103, 250-263.	6.3	596
121	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011, 20, 3289-3303.	2.9	152
122	Metaplastic breast carcinoma: tumour histogenesis or dedifferentiation?. <i>Journal of Pathology</i> , 2011, 224, 434-437.	4.5	43
123	A locus on 19p13 modifies risk of breast cancer in <i>BRCA1</i> mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010, 42, 885-892.	21.4	309
124	Adjuvant chemotherapy in older patients with breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 563-565.	27.6	2
125	Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2009, 27, 3764-3771.	1.6	89
126	C-Reactive Protein and Soluble Vascular Cell Adhesion Molecule-1 Are Associated With Elevated Urinary Albumin Excretion but Do Not Explain Its Link With Cardiovascular Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 593-598.	2.4	112



#	ARTICLE	IF	CITATIONS
127	Relation of Impaired Fasting and Postload Glucose With Incident Type 2 Diabetes in a Dutch Population. JAMA - Journal of the American Medical Association, 2001, 285, 2109.	7.4	516
128	Serum Homocysteine Levels Are Associated With the Development of (Micro)albuminuria. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 74-81.	2.4	94
129	Prognostic implications of retinopathy and a high plasma von Willebrand factor concentration in type 2 diabetic subjects with microalbuminuria. Nephrology Dialysis Transplantation, 2001, 16, 529-536.	0.7	26
130	von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 3071-3078.	2.4	277
131	Microalbuminuria and Peripheral Arterial Disease Are Independent Predictors of Cardiovascular and All-Cause Mortality, Especially Among Hypertensive Subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 617-624.	2.4	338
132	Serum homocysteine level and protein intake are related to risk of microalbuminuria: The Hoorn Study. Kidney International, 1998, 54, 203-209.	5.2	131